News

"LPC has been an important partner over the years and we are pleased to continue our relationship with them. This facility gives us an additional option in funding

Medicure also received an option to acquire all of the remaining issued shares of Apicore LLC and the holding company of Apicore US LLC, within the next 3

The approval follows a priority review of the Beleodaq new drug application (NDA) and was an Early Approval action prior to the 09 August 2014 PDUFA (Prescription Drug

The recently signed Memoranda of Understanding with researchers from Ryerson University and the University of Ottawa will contribute towards building a better knowledge base surrounding medical marijuana in

As part of the agreement, Seragon will receive an upfront cash payment of $725m from Genentech and additional contingent payments of up to $1bn based on achievement of

The company said that the currently marketed bendamustine HCI product is a lyophilized powder that requires reconstitution and dilution in 500mL of saline or a sodium chloride /

The new patent, US Patent No. 8,765,913, includes claims covering certain FZD-Fc compositions of matter and also claims covering methods of treating cancer with such soluble receptors. The

The company is focused on developing targeted and programmable therapeutics called Accurins. Both the firms have notified each other that they will not be exercising their options to

Currently, andexanet alfa is in Phase III ANNEXA (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) studies. The antidote is designed to reverse the